Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000757 47 linked products · source seen 9 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx47product presentations
G22generic molecules
DF6dosage-form groups
TA6therapeutic areas
PKR47current price records
REG40registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 2026Anti-infectives31 · 66%Pain & musculoskeletal5 · 11%Vitamins, minerals & nutrition5 · 11%Respiratory & allergy2 · 4%Gastrointestinal & hepatology2 · 4%Fluids & supportive care2 · 4%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 202647presentationsTablet21 · 45%Suspension10 · 21%Injection5 · 11%Capsule4 · 9%Syrup4 · 9%Sachet3 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 202644comparable productsBelow market median12 · 27%Near market median28 · 64%Above market median4 · 9%Company median price position-0.1%Lowest-price equivalents2Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsReign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/reign-pharmaceuticals-pcsir-klc-pvt-ltdGenerated 9 Aug 2026Semos Pharmaceuticals PVT LTD19 shared86% overlapNabiqasim Industries (Pvt) Ltd.,18 shared82% overlapBosch Pharmaceuticals (Pvt) Ltd.17 shared77% overlapNeutro Pharma (Pvt.) Ltd.,17 shared77% overlapMediate Pharmaceutical Pvt Ltd16 shared73% overlapZafa Pharmaceutical Laboratories (P…16 shared73% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Formulation footprint

Dosage forms

Tablet21 products
Suspension10 products
Injection5 products
Capsule4 products
Syrup4 products
Sachet3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1227% of comparable products
Near market median28within ±5% of median
Above market median49% of comparable products
Lowest-price equivalents2ties included
Company median price position -0.1% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Registration numbers40
Price-history records54
Products with price history6
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

47 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Renzith Azithromycin 200 mg/5 mL Dry suspension 15ml 073801 PKR 313.63 PKR 20.91/mL Near median
Renzith Azithromycin 500 mg Tablet 6's 086770 PKR 522.72 PKR 87.12/tablet Near median
Renzith Azithromycin 250 mg Tablet 6's 086771 PKR 285.13 PKR 47.52/tablet Near median
Rezo-lid Linezolid 400 mg Tablet 12's 1112663 PKR 2,112.35 PKR 176.03/tablet 24% below median
Rezo-lid Linezolid 600 mg Tablet 12's 1112664 PKR 3,698.06 PKR 308.17/tablet 22% below median
Sachets Nutrilyte Sodium chloride + Glucose + Potassium chloride + Trisodium citrate 2.6 g + 13.5 g + 1.5 g + 2.9 g Sachet 20's 073805 PKR 496.62 PKR 24.83/sachet No comparator
Sachets Rapolyte Sodium chloride + Glucose + Potassium chloride + Trisodium citrate 1.3 g + 6.75 g + 0.75 g + 1.45 g Sachet 20's 076470 PKR 408.33 PKR 20.42/sachet No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.